Research PIECES is a Deeptech Biotechnology based in Poitiers. The goals of Research PIECES are to understand the Physiology & the Physiopathology of the Central Nervous System (CNS), through Research, Development and Treatment, to find therapeutic molecules against neurological diseases as neurodegenerative diseases (Parkinson, Alzheimer, Huntington, Charcot) cancer (glioblastoma), infectious and rare diseases.

For that, they provide innovative biological preclinical models to dissect molecular, cellular and tissular mechanisms in a physiological 3D-living tissue environment. These 3D-Living Systems are physiological and tailored-made to generate robust and translatable results, and thus, avoid failing in clinical trial phases. As an alternative to animal models, they are also considered as NAMs (New Approaches Methodologies), since they can drastically reduce the number of animals used in R&D.

They provide innovative and powerful models allowing i) to accelerate the early drug discovery (screening, toxicity test), ii) to decrease the risk of failure in vivo testing and iii) to save time & money in R&D.

They also provide models for iv) the study of the environmental impact on the CNS (neurotoxins, pesticides, endocrine disruptors, frequencies, UV, ultrasounds), and v) the R&D of small medical device as micro-electrode. Research PIECES has the innovation to removes the limitations in Neurology.

SoQut Imaging is a French « deeptech » startup based in Bordeaux, founded in 2021, that revolutionizes liver disease diagnosis through innovation in medical imaging. Specializing in the early and non-invasive detection of MASH (Metabolic Associated Steatotic Liver Disease, formerly NASH), the company has developed Elibio®, a patented MRI SaaS Software. This solution delivers a « digital liver biopsy, » providing the precision of a traditional biopsy without its drawbacks (risks, costs, or invasive nature of biopsy).

The company finds its roots within University laboratories and fundamental research. Since then, SoQut has developed its DNA around medical product development, to translate R&D developments into clinically applicable technology, and better serve clinicians and patients.

To that end, Soqut gathers a multidisciplinary team, driven by an innovation mindset, with the global aim to democratize access to early diagnosis; and establish itself in clinical and pharmaceutical markets in Europe and the United States by 2027.

SoQut Imaging offers an innovative solution called Elibio®, a SaaS-based medical software integrated into existing MRI systems. This technology enables a “digital liver biopsy” by automatically analyzing medical imaging data.

It provides key indicators such as steatosis, fibrosis, and iron overload, which are essential to diagnose and monitor liver diseases, particularly MASH.

Unlike traditional biopsy, this approach is non-invasive, painless, and risk-free for patients, while also being fast (> 20 seconds MRI acquisition) and integrated into the existing radiological and clinical workflow, ensuring its smooth adoption by physicians.

Designed to assist clinicians and pharmaceutical companies in their drug development and commercialization efforts, Elibio facilitates early diagnosis and treatment monitoring : it is the new « NIT », non-invasive test the community has been waiting for, to improve patient care and sustainably transform the diagnosis of liver diseases.

Based in France, Curlim is an innovative biotech company focused on developing therapeutic solutions for hereditary peripheral neuropathies and rare neurodegenerative diseases. These debilitating conditions, such as Charcot–Marie–Tooth disease (CMT), affect tens of thousands of patients in Europe and the U.S. and currently have no curative treatments. CMT, the most common inherited peripheral neuropathy, affects approximately 1 in 5,000 individuals worldwide representing a major unmet medical need for patients worldwide.

Curlim has developed an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules for treating hereditary peripheral neuropathies and rare diseases. The benefits are better solubility, stability, and bioavailability and a significant increased intracellular penetration (Trojan horse) allowing molecules to reach full therapeutic potential.

Curlim obtained unprecedented and spectacular therapeutic effects with significant rescue in the nerve function (demonstrated on 2 CMT1A animal models with no signs of toxicity, even with repeated doses). Some highlights : very significant improvement in Motor Nerve Conduction Velocities (MNCV) in all models and a normalisation of motor skills, with balance time on the bar not statistically different from normal rats.

Moreover, the platform is a flexible solution applicable to multiple drug candidates and therapeutic indications, far beyond neuropathies.

This makes Curlim not just a drug developer, but the owner of a scalable, high-value platform technology with long-term partnering and licensing potential.

ArcaScience is a Paris-based AI healthtech company founded in 2018 to deliver AI-powered benefit-risk assessment, making drug development faster, more reliable, and ultimately safer for patients. During the COVID-19 crisis, ArcaScience was selected by the French government to structure and deliver the complete scientific corpus on the virus: an early validation of the platform’s scientific rigor at scale.

The company has reached break-even twice since late 2024. In 2025, ArcaScience closed a $7 million seed round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies. Later that year, ArcaScience Inc. was established as a US subsidiary to support its American expansion.

Today, ArcaScience’s flagship Benefit-Risk Assessment platform is in active use and has been applied to data covering over 70,000 patients, with global pharmaceutical leaders including Sanofi, AstraZeneca, GSK, and Takeda, cutting months of manual review down to days and producing fully sourced, auditable, and regulator-ready outputs. ArcaScience is building toward a future where its platform defines how the industry approaches benefit-risk assessment.

The ArcaScience Benefit-Risk Assessment platform integrates 24 specialized AI models trained on over 100 billion biomedical data points, drawn from clinical trial results, peer-reviewed literature, pharmacovigilance databases, and real-world patient records. The platform can also integrate clients’ own private datasets, keeping proprietary data fully within their local environment. Every assessment is fully sourced and traceable, eliminating the hallucinations and unsupported conclusions that make most AI tools unsuitable for regulated pharmaceutical environments. Using this platform enables clinical teams to move faster through regulatory submissions, reduce late-stage trial failures, and make benefit-risk decisions with genuine confidence.

BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancers and immunological disorders. BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancer patients with BPR001-615 a first-in-class selective BiP inhibitor at 6 months for first-in-patient clinical trials.

BiPER Therapeutics’ first clinical candidate BPR001-615 is a first-in-class oral small molecule to treat gastro-intestinal tumors by pushing cancer cells to burn out. BPR001-615 inhibits BiP, a key protein involved in cancer cell survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of patients with high BiP expression through a precision medicine approach based on overexpression level of BiP in plasma of patients. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standard of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001-615 is effective in monotherapy outperforming standard of care and enhances a wide range of standard of care agents like chemotherapies, targeted therapies and immunotherapies. Very good tolerability profile of BPR001-615 has been confirmed by toxicology studies in rats and dogs with a confirmed high NOAEL and a therapeutic index of 10 in vivo.

iAVC’s core mission is to leverage out-of-hospital data, particularly real-time patient location during emergency transfers, to optimize in-hospital care pathways and reduce critical treatment delays. The company operates at the crossroads of digital health, emergency medicine, and organizational innovation. iAVC has built a strong institutional network, engaging with France’s Ministry of Health, the HAS, the Agence du Numérique en Santé, and regional health authorities. It has also established a scientific committee including leading figures from French neurology and interventional neuroradiology. Backed by Eurasanté as a shareholder and supported by France 2030 regional funding, iAVC holds a French patent and is actively expanding its patent coverage to Europe, the United States, and Saudi Arabia. The company is currently deploying its first commercial pilots and anticipates full-scale market expansion from 2028 onwards.

ROMAIN is iAVC’s digital health solution designed to eliminate a fundamental problem in emergency care : hospitals are notified that a critical patient is on the way, but don’t know when he will actually arrive. This uncertainty generates cascading organizational failures and preventable delays that directly worsen patient outcomes. In stroke care, every 30 minute delay generates an estimated 15% increase in lifelong disability. ROMAIN solves this for inter-hospital transfers by combining a GPS bracelet placed on the patient’s ankle at the sending hospital with a secure application used by the receiving team. The system delivers real-time location tracking, estimated time of arrival, and automatic customizable alerts, enabling receiving teams to mobilize in a just-in-time manner. As of February 2026, ROMAIN has been deployed across four major university hospitals in France (Lille, Bordeaux, Nancy and Reims), covering 10% of inter-hospital stroke transfers, with strong adoption across the full multidisciplinary team. The solution is classified as an organizational tool, not a medical device, and is being expanded to cover pre-hospital pathways through interoperability connectors with EMS dispatch systems, emergency transport operators, and fire services.

Oria Bioscience is a French biotechnology company specializing in the isolation and supply of native, functional organelles compatible with screening assays. Organelles are the functional units inside cells where critical biological processes occur. Lysosomes control degradation, recycling, and cellular stress responses. Mitochondria generate cellular energy and regulate metabolic and cell death pathways. The endoplasmic reticulum governs protein and lipid synthesis and maintains cellular balance. Dysfunction at the organelle level is a key driver of many diseases, making these structures essential and actionable therapeutic targets. Oria Bioscience isolates intact organelles, at high throughput, while preserving their native membranes and biological activity, enabling direct access to intracellular targets in a physiologically relevant context. Working at the organelle level reduces experimental complexity and improves data quality across early drug discovery.

The platform is used by pharmaceutical companies, biotechnology firms, and contract research organizations seeking more predictive research tools, delivering faster decision-making, higher ROI on candidate selection, and significant reductions in development time and costs. LYSO-Preps is Oria Bioscience’s first product : a tube of ready-to-use, purified native lysosomes adapted for drug discovery and especially screening applications. Lysosomes play a central role in cellular recycling, metabolism, and stress regulation, and their dysfunction is involved in numerous diseases: Alzheimer, Parkinson’s etc… LYSO-Preps are functional lysosomes preparation with preserved biological activity, allowing direct and reliable interrogation of lysosomal targets.

bYoRNA is developing a platform for designing and manufacturing messenger RNA in yeast, rather than through in vitro transcription (IVT), to produce less immunogenic, less expensive, and more effective drugs. The target market is threefold: cancer immunotherapies, vaccines against infectious diseases, and gene therapies for rare diseases.

Long RNAs (> 5,000 nucleotides) enable gene therapies that are 10x more precise and cancer vaccines that are 50x less immunogenic. However, 99% of long RNAs produced by IVT are fragmented and unusable, whereas yeast can produce them naturally. Since 2022, the founders, Pascal Viguié (MSc Oxford-MBA Columbia, entrepreneur with a €30M exit), Thierry Ziegler (PhD, formerly at SANOFI, MERCK & CELLECTIS), and Chantal Pichon (PhD, inventor of the patent), supported by a team of 10 people, have quadrupled the length of the RNA produced, increased the yield 80-fold and increased the purity 100-fold (from 0.1% to 10%). Their collaborations on long RNAs with a major veterinary pharmaceutical company and the academic branch of a global mRNA leader will result in royalties ranging from 1 to 5%, as they enable these players to target new markets. By the end of 2026, after animal testing, they will approach BioNTech, Moderna, and Strand Therapeutics.

bYoRNA’s cell-based factory allows producing mRNA within yeast sub-compartments which protect the RNA from degradation. This technology was patented in 2018 (WO2018/171946) in Europe and the USA. bYoRNA’s solution enables the production of conventional and long mRNA, solving the challenge of manufacturing long mRNA (>5,000 nucleotides).

.

Cohesives is a French deeptech medical device company based in Dijon, Burgundy, developing a technological platform called AnCor®, the first effective adhesive for wet biological tissues. The company is developing three medical devices based on AnCor®: an internal surgical suture sealant, a skin substitute for chronic wounds, and a liquid bandage. The liquid bandage has already been licensed to a strategic player for OTC applications, with first sales expected in 2026 and initial royalty revenues in 2027.

Cohesives is composed of an experienced 7-person team led by Dr. Bertrand Perrin, a former cardiovascular surgeon, and has in-house manufacturing capabilities adapted to clinical development. AnCor® is a photopolymerizable adhesive designed for biological tissues. It anchors to the surface of tissues by penetrating them before being cured by UV light, offering unmatched adhesion properties. It is currently one of the only solutions able to effectively adhere to wet internal tissues. The technology also provides strong sealing properties, helping retain wound exudates.

Cohesives plans to develop a skin substitute for the treatment of chronic wounds in the coming years. In parallel, Medical Brands has developed a liquid bandage using AnCor® for small cuts and skin cracks. The company is currently seeking a US distributor, with a planned launch in the United States by the end of 2026 and in Europe in 2027. AnCor® is protected by 22 patents.

Addidream delivers high‑fidelity 3D anatomical models and surgical training solutions that help hospitals and medtech companies reduce surgical risk, accelerate learning curves, and validate new devices more efficiently. The company’s mission captures its value: “Provide safer surgical care by delivering high‑fidelity 3D anatomical models and tailored training solutions for surgical rehearsal and preoperative planning.” These models replicate cortical and cancellous bone structures, soft tissues (Addi‑SOFT), and skin envelopes (Addi‑SKIN), enabling realistic procedure rehearsal and preoperative planning. As described in its materials, Addidream builds “Realistic 3D anatomical models (cortical/cancellous bone, Addi‑SOFT soft tissues, Addi‑SKIN envelopes)” allowing for realistic cutting, drilling, suturing, and device deployment.
Addidream serves surgeons, training centers, and medical device manufacturers seeking scalable, customizable simulation tools that improve clinical performance and support regulatory pathways. Its differentiation lies in clinician co‑development, superior haptic realism, and patient‑specific manufacturing based on CT data. This positions the company as a strategic partner for organizations aiming to shorten training cycles, reduce OR time, and de‑risk device launches through reproducible, high‑impact simulation.

Beyond individual models, Addidream provides integrated simulation platforms that support procedure rehearsal, curriculum development, and device evaluation under controlled, repeatable conditions. These solutions are fully customizable—from patient‑specific CT‑based replicas to standardized training modules—allowing hospitals, training centers, and medtech R&D teams to scale programs efficiently.